regulating IL-2 and IL-4 secretion and promoting Th2 polarization. 6 In addition to its effects on normal cells, IL-6 also contributes to the pathogenesis of a number of inflammatory and malignant conditions including Crohn's disease, systemic idiopathic juvenile arthritis and rheumatoid arthritis as well as a number of other disorders. Our findings suggest that CLL should now be added to this list and are in keeping with reports that elevated serum levels of this cytokine correlate with advanced disease and adverse outcome. 7, 8 It is now clear that bi-directional interactions between various non-neoplastic stromal and immune cells and the tumor are crucially important both for the maintenance and progression of the malignant clone in CLL and the induction of immune dysfunction that is such a hallmark of the disease. 2 The results presented here have several implications for understanding these aspects of CLL pathogenesis. Firstly, IL-6 or secondary cytokines may promote disease progression either directly through effects on cell survival and proliferation or indirectly through effects on the microenvironment, for example, by causing T cells to secrete IL-4 or through IL-6-induced VEGFmediated neovascularization. In addition, IL-6 may contribute to the complex immunopathology of CLL through its inhibitory effects on T cell activation, the CD40L system and induction of a Th2 cytokine response, which may lead to defective cellular and humoral immunity and a propensity to autoimmunity. As well as its potential effects on the tumor and normal immune system, IL-6 is an important inflammatory mediator and induces fever and the acute-phase response. Advanced CLL is frequently associated with fever and lethargy and elevated IL-6 levels might thus play a role in this troublesome constellation of symptoms. Finally, our findings are of potential relevance to the treatment of CLL since blockade of IL-6 signaling, either by neutralizing or receptor blocking agents, might slow disease progression and reduce the systemic symptoms and immune dysfunction that are such a central feature of CLL. The Wilms' tumor gene WT1 is expressed only in hematopoietic progenitor cells and not in mature blood cells. In accordance, high levels of WT1 are found in acute myeloid leukemia blast cells, a cell type characterized by an immature phenotype. 1 The expression of the WT1 transcription factor in leukemic cells is proposed to exert an antiapoptotic effect. Investigation of the mechanisms by which WT1 regulates apoptosis has revealed that several bcl-2 family members are induced by WT1, including bcl-2 itself, the proapoptotic family members Bak and Bax, and the anti-apoptotic family member Bfl-1/A1. Nevertheless, there are conflicting reports whether bcl-2 is the main WT1 target in an antiapoptotic phenotype. The transcription factor human cyclin-dependent myb-like protein 1 (hDMP1, hDMTF1), a critical and positive regulator of the ARF tumor suppressor, is highly expressed in terminally differentiated cells. Given the differentiation block seen in acute myeloid leukemia, we were asking if DMP1 might be a new WT1-repressed transcriptional target.
Although the function of DMP1 as tumor suppressor and physiological regulator of the ARF-p53 pathway is well documented in mouse models, its role in human cancers remains largely unknown. In a gene profiling experiment, Elmaagacli et al.
2 recently observed that hDMP1 is induced when targeting WT1 with small interfering RNA in K562 leukemic cells. Additionally, the WT1 knockdown was associated with reduced proliferation in these cells. Furthermore, it has been shown that WT1 is downregulated during the differentiation of leukemic cells, paralleled by decreased proliferation. Given the above observations, we asked whether the cell cycle inhibitor hDMP1 is induced during this process. To this end, NB4 leukemic cells were treated with all-trans retinoic acid (ATRA) or phorbol-12-myristate-13-acetate (PMA), to differentiate these cells toward neutrophil-or macrophagelike cells, respectively. Successful differentiation was monitored by CD11b expression and morphology. We found a 7.4-and 2.6-fold increase of hDMP1 mRNA during neutrophil and macrophage differentiation, respectively. This increase in hDMP1 mRNA levels was paralleled by a 90 and 70% decrease in WT1 message (Figure 1a ). To confirm our data in a different model for hematopoietic development, we repeated the above experiments with HL60 leukemic cells. A 2.9-and 2.7-fold increase was seen during ATRA-and PMA-induced differentiation, respectively. Additionally, we induced monocytic development in HL60 cells using VitD 3, leading to a 1.9-fold increase of hDMP1 mRNA. As with NB4 cells, all differentiation experiments in HL60 led to a 70-90% decrease of WT1 mRNA (Figure 1b) . To determine whether hDMP1 levels increase during myeloid differentiation in primary hematopoietic cells, we differentiated cord blood CD34 þ progenitors toward granulocytes using human recombinant granulocyte-colony stimulating factor, as described previously. 4 The progenitor cells were first expanded and then differentiated. hDMP1 was upregulated 3.5 and 3.4-fold during the differentiation period (Figure 1c ). G-CSF receptor mRNA was upregulated 25-and 63-fold in these two fresh cord blood samples, respectively, confirming successful granulocytic differentiation. Our findings show that WT1 downregulation during myeloid differentiation of NB4 and HL60 leukemic cell lines is associated with increased hDMP1 mRNA levels.
To evaluate whether WT1 represses hDMP1 transcription, in the absence of differentiation, we ectopically expressed WT1 in WT1-negative U937 leukemic cells. 5 Expression of WT1 led to a 50% decrease in hDMP1 transcript levels. Moreover, expression of WT1 in these cells markedly inhibited induction of hDMP1 upon ATRA or PMA treatment. The induction of hDMP1 in parental U937 cells was 6.3-and 4-fold, whereas in U937-WT1 hDMP1 induction was only 1.9-and 1.4-fold (Figure 1d ).
To assess whether WT1 directly affects hDMP1 transcription, we next performed promoter-reporter assays in H1299 nonsmall cell lung cancer cells that do not express detectable WT1 protein levels. The WT1 (À/À) isoform significantly inhibited the transcriptional activity of the full-length hDMP1 promoter construct in a dose-dependent manner (Figure 2a) . Similar repression of the hDMP1 promoter was seen when cotransfecting the WT1 (À/ þ ), ( þ / þ ) and ( þ /-) isoforms (data not shown). In order to identify the WT1 repressive element in the hDMP1 promoter, we tested a series of deletion constructs and could show that the WT1 responsive element lies within Figure 1 Inverse correlation of hDMP1 and WT1 expression during myeloid differentiation. (a) NB4 cells were treated with ATRA (1 mM) or PMA (10 ng/ml) for 4 days. Primers and probes detecting all WT1 isoforms were described.
3 Primers and probes for specific amplification of fulllength hDMP1 transcripts were as follows: forward 5 0 -CCATGTGGGAAAATATACACCTGAA-3 0 ; reverse 5 0 -CCCTATTGTTGCCCAGTCATTG-3 0 ; probe FAM-AGAAGCTCAAGGAGCTCCGGATAAAGCAT-TAMRA. For each sample, the relative expression normalized to PBGD (forward 5 0 -GGCAATGCGGCTGCAA-3 0 ; reverse 5 0 -GGGTACCCACGCGAATCAC-3 0 ; probe FAM-CTCATCTTTGGGCTGTTTTCTTCCGCCT-TAMRA) was calculated using the comparative C t method. Data are depicted relative to that expressed in nontreated cells. Bars, s.d (b) HL60 cells were treated and results were analysed as in (a). Additionally, HL60 cells were differentiated toward monocytic-like cells using VitD 3 (10 nM). (c) hDMP1 and G-CSF-R mRNA expression during in vitro differentiation of CD34 þ progenitor cells. Analysis was as in (a). (d) WT1 null parental and stably expressing WT1 U937 cells were differentiated using ATRA and PMA. The mRNA expression was analysed as in (a). WT1 expression was confirmed by western blotting (right panel).
Letters to the Editor 300 bp upstream of exon 1 (data not shown). This 300 bp hDMP1 promoter region contains a putative overlapping early growth responsive gene 1 (EGR-1) and specificity protein 1 (SP1)binding site. 6 It has been shown that WT1 occasionally binds to EGR1 binding sites. 7 We therefore mutated the EGR/ SP1 site in the hDMP1 promoter and tested for WT1-induced repression. We found that the 2.3 and 0.3 kb hDMP1 promoter constructs are inhibited upon WT1 co-transfection, but not the 0.3 kb construct with a mutated EGR/SP1 binding site (Figure 2b ). Of note, the EGR/SP1 site is important for basic promoter activity as can be seen by the lower activity of the mutated reporter compared to the wild-type reporter. In line, mutating the conserved EGR/SP1 site in the mouse Dmp1 promoter leads to a significant loss of its activity. 6 In vitro binding of WT1 to an oligo containing the EGR/SP1 site was seen in band shift assays (data not shown). We further analyzed in vivo binding of endogenous WT1 to the proximal hDMP1 promoter in HL60 cells using chromatin immunoprecipitation. An enrichment of WT1 at the proximal hDMP1 promoter was seen only when WT1 antibody was used (Figure 2c ). These results suggest that WT1 inhibits hDMP1 transcription via direct binding to an EGR/SP1 site in the proximal hDMP1 promoter.
Altogether, our results demonstrate that hDMP1 is suppressed by WT1 in leukemic cells via direct binding to an EGR/SP1 site. The identification of direct transcriptional repression of hDMP1 by WT1 delineates a new oncogenic WT1 mechanism of control in the hematopoietic system. The location of the EGR1-, SP1-and E2F-binding sites in the proximal DMP1 promoter is indicated by black, gray and white ovals, respectively. The arrow shows the transcription start site of the hDMP1 gene. For the reporter assay, 100 ng of reporter and WT1 (À/À) expression plasmid or pcDNA3.1 vector were co-transfected. Analysis was as in (a). (c) WT1 binds to the DMP1 promoter in vivo. Chromatin immunoprecipitation assay using HL60. Briefly, cells were cross-linked with 1% formaldehyde, stopped with glycine and rinsed twice with PBS. DNA was enzymatically digested and protein DNA complexes were enriched by immunoprecipitation using antibody against WT1. AntiPol II and IgG served as positive and negative controls, respectively. PCR was performed using primers comprising the EGR/SP1 site in the hDMP1 promoter (forward: 5 0 -AGCCGGAAGTGACGCGTACA-3 0 ; reverse: 5 0 -AGTGGCTGCAGCTGGAGTGAG-3 0 ).
Letters to the Editor
Interferon-a is able to maintain complete molecular remission induced by imatinib after its discontinuation
Leukemia ( The induction of myeloblastin (MBN) expression by interferon-a (IFN-a), but not by imatinib, may contribute to the specific ability of IFN-a to induce an MBN-specific T-cell response in chronic myeloid leukemia (CML) patients. 1 We report here the clinical outcome for five CML patients who received low-dose IFN-a when CML was undetectable after imatinib. At the time of complete molecular remission (CMR) achieved by imatinib, all patients discontinued imatinib for intolerance and were 'maintained' successfully with IFN-a alone. Written informed consent was obtained from all patients.
Patient 1 was a 66-year-old woman with CML diagnosed in October 1992. She received chemotherapy and autografting. Available evidence suggests that BCR-ABL kinase inhibitor therapy (imatinib, nilotinib and dasatinib) is not curative; moreover, the risk of harboring BCR-ABL-independent leukemic cell clones might increase with the 'biologic age' of the disease. IFN-a appears to induce remissions from CML by eliciting an MBN-specific T-cell response. 4 Recent results suggest that the induction of MBN expression may be a part of this response mechanism because sole expression of tumor-specific genes in antigen-presenting cells or loading of tumor peptides onto antigen-presenting cells has been shown to induce a potent human leukocyte antigen class I-restricted, tumor-specific cytotoxic T-lymphocyte response. [5] [6] [7] Indirect evidence for a central role of MBN expression in the generation of a T-cell response is provided by the fact that all tested human leukocyte antigen-A0201 IFN-a-treated patients, but only 2 of 11 imatinibtreated patients, developed PR1-specific cytotoxic T lymphocytes. 1 This also implies that the character of remissions achieved with IFN-a and imatinib may not be equivalent and, therefore, a sequential combination therapy of imatinib and IFN-a, using their different effector mechanisms, may be more effective in the treatment of CML than any current monotherapy. The first preliminary data presented here seem to confirm the efficacy of IFN-a given to CMR patients after imatinib discontinuation.
